New antibody drug takes aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…
Phase: PHASE1 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC